In cardiometabolic contexts such as DM2 and HTN, agents like SGLT2 inhibitors and AMPK/Sirtuin modulators illustrate how metabolic correction can dovetail with oxidative protection. This evidence concerns the gene SLC5A2 and myotonic dystrophy type 2.